Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Notes Payables (2016 - 2021)

Adma Biologics' Notes Payables history spans 7 years, with the latest figure at $100.0 million for Q1 2021.

  • For Q1 2021, Notes Payables changed N/A year-over-year to $100.0 million; the TTM value through Mar 2021 reached $100.0 million, changed N/A, while the annual FY2020 figure was $100.0 million, 37.93% up from the prior year.
  • Notes Payables reached $100.0 million in Q1 2021 per ADMA's latest filing, roughly flat from $100.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $100.0 million in Q4 2020 to a low of $6.7 million in Q1 2017.
  • Average Notes Payables over 5 years is $57.3 million, with a median of $72.5 million recorded in 2019.
  • Peak YoY movement for Notes Payables: tumbled 63.07% in 2017, then skyrocketed 141.67% in 2019.
  • A 5-year view of Notes Payables shows it stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then soared by 141.67% to $72.5 million in 2019, then soared by 37.93% to $100.0 million in 2020, then changed by 0.0% to $100.0 million in 2021.
  • Per Business Quant, the three most recent readings for ADMA's Notes Payables are $100.0 million (Q1 2021), $100.0 million (Q4 2020), and $85.0 million (Q3 2020).